Figure 7. PXD101 effects on expression of cyclin-dependent kinase inhibitors (CKI) p21 and p27 and modification of p53. (A and B) The cell lines shown were treated with PXD101 for 0, 2, 4, 8, 24, 48, and 72 h. Whole cell extracts were generated and subjected to western blotting with antibodies against p21, p27, hsp90, α-tubulin, or GAPDH. PXD101-resistant cell lines are shown in (A) while PXD101-sensitive cell lines are shown in (B). (C and D) Cells were treated with PXD101 (P), doxorubicin (2 μM) (D), or Nutlin-3A (10 or 20 μM) (N) for 8 or 24 h. Whole cell extracts from treated and untreated cells were generated and subjected to western blotting with the antibodies indicated. PXD101-resistant cell lines are shown in (C) while PXD101-sensitive cell lines are shown in (D). The blots shown are representative of 3 independent experiments.